Hospital Virgen de la Victoria, Málaga, CIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Spain.
Biochem J. 2010 Aug 15;430(1):141-9. doi: 10.1042/BJ20100285.
A paradoxical but common finding in the obesity clinic is the identification of individuals who can be considered 'inappropriately' healthy for their degree of obesity. We think that studying these obese but metabolically healthy individuals and comparing them with equally obese but insulin-resistant individuals could provide important insights into the mechanistic link between adipose tissue expansion and associated metabolic alterations. In the present study, we investigated whether there are differences in inflammatory and insulin signalling pathways in VAT (visceral adipose tissue) that could account for the metabolic differences exhibited by morbidly obese individuals who are either insulin-resistant (IR-MO) or paradoxically insulin-sensitive (NIR-MO). Our results indicate that there are pathways common to obesity and unrelated to insulin resistance and others that are discriminative for insulin resistance for a similar degree of obesity. For instance, all morbidly obese patients, irrespective of their insulin resistance, showed increased expression of TNFalpha (tumour necrosis factor alpha) and activation of JNK1/2 (c-Jun N-terminal kinase 1/2). However, the IR-MO group showed significantly elevated expression levels of IL (interleukin)-1beta and IL-6 and increased macrophage infiltrates compared with non-obese individuals and NIR-MO. IkappaBalpha [inhibitor of NF-kappaB (nuclear factor kappaB) alpha], the activation of ERK1/2 (extracellular-signal-regulated kinase 1/2) and NF-kappaB were discriminative of the state of insulin resistance and correlated with differential changes in IRS-1 (insulin receptor substrate 1) expression and Akt activation between IR-MO and NIR-MO individuals. Our results support the concept that NIR-MO individuals lack the inflammatory response that characterizes the IR-MO patient and that IL-6, IL-1beta, ERK and NF-kappaB are important effectors that mediate the inflammation effects promoting insulin resistance.
在肥胖诊所中,一个矛盾但常见的发现是,有些人的肥胖程度与他们的健康状况不成比例,他们被认为是“不适当”健康的。我们认为,研究这些肥胖但代谢健康的个体,并将其与同样肥胖但胰岛素抵抗的个体进行比较,可以为脂肪组织扩张与相关代谢改变之间的机制联系提供重要的见解。在本研究中,我们研究了代谢健康的肥胖个体(NIR-MO)和胰岛素抵抗的肥胖个体(IR-MO)内脏脂肪组织(VAT)中是否存在炎症和胰岛素信号通路的差异,这些差异可能解释了这些肥胖个体的代谢差异。我们的结果表明,肥胖相关的通路与胰岛素抵抗无关,但也有一些通路与肥胖程度相似的胰岛素抵抗有关。例如,所有肥胖患者,无论其胰岛素抵抗程度如何,TNFalpha(肿瘤坏死因子 alpha)的表达和 JNK1/2(c-Jun N-末端激酶 1/2)的激活都增加。然而,与非肥胖个体和 NIR-MO 相比,IR-MO 组的 IL(白细胞介素)-1beta 和 IL-6 表达水平显著升高,且巨噬细胞浸润增加。IkappaBalpha(NF-kappaB(核因子 kappaB)alpha 的抑制剂)、ERK1/2(细胞外信号调节激酶 1/2)和 NF-kappaB 的激活是胰岛素抵抗状态的鉴别因素,与 IRS-1(胰岛素受体底物 1)表达和 Akt 激活的差异变化相关,这些变化在 IR-MO 和 NIR-MO 个体之间存在差异。我们的研究结果支持这样一种观点,即 NIR-MO 个体缺乏表征 IR-MO 患者的炎症反应,而 IL-6、IL-1beta、ERK 和 NF-kappaB 是介导炎症作用促进胰岛素抵抗的重要效应因子。